BioSpace News Archive

GAZYVA is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.

Seattle Genetics, Inc., (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1).

Tenured Expert with Successful Track Record in Mature Managed Care Markets to Spearhead Acceleration Toward Value-Based Care and Reimbursement Models

Trovagene, Inc. provided an update on key value-creating milestones for the second half of 2018 and a review of its year-to-date achievements.

Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel

PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation

Catabasis Pharmaceuticals, Inc. today announced plans for the Phase 3 POLARIS DMD trial with edasalonexent in patients with Duchenne muscular dystrophy (DMD).

Emmaus Life Sciences today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for L-glutamine as a treatment for diverticulosis.

Pharmagreen Biotech, Inc. is pleased to announce that its wholly owned Canadian subsidiary, WFS Pharmagreen Inc., has completed the design and is in the process of finalizing the engineering plans of an exceptional project to develop and construct the state of the art Cannabis research and production facility.

Leading Health Group Adds Heather Ata to Executive Leadership Team